Merck has agreed to pay more than $671 million to settle allegations of fraud concerning Medicaid and other public healthcare programs across the U.S., according to a federal Settlement Agreement. According to qui tam lawyers Steven H. Cohen, Mark Kleiman and BethAnne Yeager, Merck employed four marketing tactics to maintain market share for drugs including Vioxx, Zocor, Cozaar, Fosamax, Maxalt, and Singulair. This practice known as “nominal pricing” concerned discounts on drugs alle...